Job Trends
The recalibration will also have workforce implications, including an overall workforce reduction of approximately 20% during Q1, 2021.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
THE LATEST
Medical device firm Caisson Interventional LLC plans to expand its Maple Grove facilities by 30,000 square foot and add 50 jobs.
This biotech could potentially be a better value.
Visterra has outgrown its headquarters and is moving to a site double the size in suburban Waltham, MA.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
This is a market like the world has never seen.
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.
The FDA’s Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.